Figure 4. Simultaneous evaluation of Idelalisib and Ibrutinib.
Cross reactivity of ibrutinib and idelalisib according to their ex vivo pharmacological profile. Red samples represent the ibrutinib resistant samples.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.